查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球細胞表面標記物檢測市場 - 2023-2030
市場調查報告書
商品編碼
1279707

全球細胞表面標記物檢測市場 - 2023-2030

Global Cell Surface Markers Detection Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球細胞表面標記物檢測市場規模預計將在 2022 年達到 49.765 億美元，並在 2030 年達到 95.226 億美元，增長勢頭強勁。 在預測期內（2023-2030 年），該市場的複合年增長率將達到 8.7%。

細胞表面標記檢測用於通過流式細胞術使用特定抗體結合的特定膜蛋白（即表面標記）來分離熒光細胞。 用於通過熒光激活細胞分選 (FACS) 分析識別和純化人類造血幹細胞的細胞表面標記檢測包含許多分化簇 (CD) 標記。 最原始的人類造血幹細胞已被鑑定為 CD34+CD90+，其他細胞群為 CD34+CD38。

即使在沒有CD45RA表達的情況下，它也可以與上述標記物結合使用來鑑定原始造血幹細胞。 人多能祖細胞被鑑定為 LinCD34+CD38CD90c-kitloflt3loCD133+CD45RA。 CMP（紅細胞、粒細胞、巨核細胞、巨噬細胞）和 CLP（B 細胞、T 細胞、NK 細胞）的分化後代在 FACS 分析中通過譜系特異性標記物的存在來區分。 如B淋巴細胞為CD45+CD20+CD24+，T淋巴細胞為CD45+CD3+，巨核細胞為CD42b+，粒細胞為CD45+CD15+CD24+CD114+CD182+，巨噬細胞為CD45+CD68+。

市場動態

診斷的興起、對精準醫學的需求和技術進步推動了市場增長

精準醫學是一個旨在根據特定患者群體的分子和環境因素提供醫療服務的概念。 生物標誌物輔助治療是精準醫學的一個重要分支學科，包括促進突變、蛋白表達、mRNA、MSI（微衛星不穩定性）、腫瘤突變負荷（TMB）、表觀遺傳生物標誌物等的增加。 生物標誌物基於 DNA、mRNA 和蛋白質，包括易化子突變、蛋白質表達、mRNA、MSI、腫瘤突變負荷 (TMB) 和表觀遺傳生物標誌物。

流式細胞術、免疫組織化學 (IHC) 和新一代測序（RNA 測序）是用於鑑定或診斷人群中細胞表面標誌物檢測的方法。 RNA-Seq 使用新一代測序技術對 cDNA 進行並行測序，產生大量描述 RNA 片段中鹼基對序列的數據。 用於細胞表面標記物檢測的更多和更快的診斷正在推動市場。

設備成本高

流式細胞術等昂貴的設備及其複雜性是阻礙市場增長的主要原因。 流式細胞術的成本因地區而異，但非常昂貴。 例如，有索尼等廠家已經開始做10萬日元以下的流式細胞儀設備，但一台10萬到50萬日元之間仍有可能。 因此，這是抑制細胞表面標記檢測市場增長的主要因素。

COVID-19 影響分析

COVID-19 大流行預計將對市場產生重大影響，因為細胞表面標記物檢測附著在細胞膜上，並在細胞間信號傳導中發揮重要作用。 考慮 COVID-19 抗體與細胞表面標記檢測相互作用的研究項目正在進行中，包括比較 COVID-19 患者和健康對照單核細胞中的細胞表面標記檢測。

這項研究發現 COVID-19 患者的真菌合併感染率很高，這導致創新方法可以更好地了解該疾病並找到治療方法。 此外，細胞表面標記檢測已被用於研究 COVID-19 在大流行期間的影響。

俄烏衝突分析

俄烏衝突正在全球範圍內產生負面影響，尤其是在東歐、歐盟、東/中亞和美國。 對烏克蘭的負面影響，預計對俄羅斯的長期影響。 戰爭會影響供需平衡、價格波動、進出口、貿易，並對細胞表面標記物檢測市場產生短期影響。

內容

第一章調查方法及範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 按產品分類的片段
  • 片段：按應用
  • 區域摘要

第四章市場動態

  • 影響因素
    • 主持人
      • 診斷的增加、對精準醫學的需求、技術進步
    • 約束因素
      • 設備成本增加
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法律法規分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • COVID-19 期間的情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格和動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章副產品

  • 流式細胞儀
  • 血液分析儀
  • 細胞成像系統
  • 試劑和試劑盒
  • 其他

第八章應用

  • 疾病診斷與鑑定
  • 研究和藥物發現
  • 其他

第9章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第10章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第11章公司簡介

  • 商務部
    • 公司簡介
    • 產品組合和說明
    • 財務摘要
    • 主要發展狀況
  • Nihon Kohden Corporation
  • Sysmex Corporation
  • Thermo Fisher Scientific
  • Nexcelom Bioscience LLC
  • Beckman Coulter Inc.
  • Qiagen NV
  • IVD Medical Holding Limited（Immucor Inc.）
  • Agilent Technologies Inc.
  • Luminex Corporation.

第12章 附錄

簡介目錄
Product Code: MD3902

Market Overview

The global cell surface markers detection market size reached US$ 4,976.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 9,522.6 million by 2030. The market is exhibiting at a CAGR of 8.7% during the forecast period (2023-2030).

The cell surface marker is used to separate fluorescent cells by flow cytometry by using a specific membrane protein (i.e., surface marker) bound by a specific antibody. The cell surface markers used for the identification and purification of human HSCs by fluorescence-activated cell sorting (FACS) analysis incorporate a number of clusters of differentiation (CD) markers. The most primitive human HSC is identified as CD34+CD90+, while other groups have identified it as CD34+CD38.

Absent expression of CD45RA has also been used in combination with the above markers for the identification of primitive HSCs. Human multipotent progenitor cells are identified as LinCD34+CD38CD90c-kitloflt3loCD133+CD45RA. Differentiated progeny of CMP (erythrocytes, granulocytes, megakaryocytes, and macrophages) and CLP (B cell, T cell, NK cell) is identified by the presence of lineage-specific markers in FACS analysis. For Instance, B- lymphocytes are CD45+CD20+CD24+, T-lymphocytes are CD45+CD3+, megakaryocytes are CD42b+, granulocytes are CD45+CD15+CD24+CD114+CD182+, and macrophages are CD45+CD68+.

Market Dynamics

Increased Diagnostics, Demand For Precision Medicine, And Technological Advancements Drive The Market Growth

Precision medicine is a concept that aims to align medical care with the molecular and environmental factors of certain patient groups. Biomarker-supported therapy is an essential sub-discipline of precision medicine, which includes driver mutations, protein expression, mRNA, MSI (microsatellite instability), tumor mutational burden (TMB), and epigenetic biomarkers. Biomarkers are DNA-, mRNA-, or protein-based and include driver mutations, protein expression, mRNA, MSI, tumor mutational burden (TMB), and epigenetic biomarkers.

Flow Cytometry, Immunohistochemistry (IHC), and Next Generation Sequencing (RNA Sequencing) are methods used to identify or diagnose the cell surface markers in a population. RNA-Seq uses next-generation sequencing to sequence cDNA in parallel to create large amounts of data showing the sequence of base pairs found in RNA fragments. Increased and quick diagnostics for cell surface markers detection drives the market.

High Cost of the Instruments

Expensive instruments like flow cytometry and their complexity are the main reasons to hamper the market growth. The cost of the flow cytometry varies from region but it is very expensive. For instance, some manufacturers, such as Sony, are beginning to build flow cytometer instruments that cost under $100,000, but it's still possible to spend anywhere from $100,000 to $500,000 for a single unit. So, this is the main factor hindering the market growth of cell surface markers detection.

COVID-19 Impact Analysis

The COVID-19 pandemic is expected to have a significant impact on the market, as cell surface markers are attached to the cell membrane and play a crucial role in intercellular signaling. Research projects are being conducted that involve the interaction of COVID-19 antibodies with cell surface markers, such as comparing the cell surface marker expression on monocytes of COVID-19 patients with healthy controls.

This study found an increased rate of fungal co-infections in COVID-19 patients, leading to a better understanding of the disease and innovative ways to find a cure. The cell surface markers are also used to study the effect of COVID-19 during the pandemic.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine Conflict has caused negative impacts globally, particularly in Eastern Europe, the European Union, Eastern & Central Asia, and the United States. It is expected to have an adverse impact on Ukraine and long-term effects on Russia. Due to the wars, implications for demand-supply balances, pricing variants, import/export and trading, short-term impact can be seen in the cell surface markers detection market.

Segment Analysis

The global cell surface markers detection market is segmented by product and by application.

Flow Cytometry Segment is Expected to dominate the market growth

Flow cytometry is a technique used to detect the presence of cell types within a population by passing single cells through a highly focused laser. Antibodies specific to cell surface markers of interest are added to a sample and allowed to bind to the cells. These antibodies are conjugated to fluorochromes which emit light at various wavelengths. The population of cells is then passed through a laser, exciting the fluorochromes and capturing the light emitted.

The cells are then sorted into subpopulations based on the markers present through a series of histograms and dot plots called a gating strategy. Flow cytometry allows for multiple cell surface markers on a cell to be detected, but nonspecific binding and spectral overlap can become a limitation. Flow cytometry also does not allow for the spatial aspect of a sample to be analyzed as the cells are suspended and fed through the laser one at a time. The flow cytometry segment holds about 37.6% of the total cell surface markers market in the forecast period owing to its multiple advantages in analysing cell surface markers.

Geographical Analysis

The Strong Presence Of The Clinical Research Sector And Increased Awareness About Cell Surface Markers

The North America region holds the largest share of the global cell surface markers detection market accounting for approximately 39.7% in the forecast period owing to the strong presence of the clinical research sector in the region's developed economies. The presence of leading players in the medical research sector has elevated the medical research sector in North America and the strong presence of cellular researchers in North America is likely to be a major driver for the market. The increased awareness about the cell surface markers is more likely to drive the market in North America.

Competitive Landscape

The major global players in the market include: BD, Nihon Kohden Corporation, Sysmex Corporation, Thermo Fisher Scientific, Grifols, Bio Rad Laboratories Inc., Agilent Technologies Inc., Nexcelom Bioscience LLC, Beckman Coulter Inc., IVD Medical Holding Limited (Immucor Inc.), and Luminex Corporation.

Why Purchase the Report?

  • To visualize the global cell surface markers detection market segmentation based on product, application, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of cell surface markers detection market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global Cell Surface Markers Detection Market report would provide approximately 54 tables, 46 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Application
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased Diagnostics, Demand for Precision Medicine, and Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of the Instruments
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Flow Cytometry*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Hematology Analyzers
  • 7.4. Cell Imaging Systems
  • 7.5. Reagents and Kits
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Disease Diagnosis And Identifications*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Research And Drug Discovery
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. BD*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Nihon Kohden Corporation
  • 11.3. Sysmex Corporation
  • 11.4. Thermo Fisher Scientific
  • 11.5. Nexcelom Bioscience LLC
  • 11.6. Beckman Coulter Inc.
  • 11.7. Qiagen NV
  • 11.8. IVD Medical Holding Limited (Immucor Inc.)
  • 11.9. Agilent Technologies Inc.
  • 11.10. Luminex Corporation.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us